Advertisement


Sara A. Hurvitz, MD: New Findings on Neoadjuvant Trastuzumab Deruxtecan and Anastrozole in Early-Stage Breast Cancer

2022 San Antonio Breast Cancer Symposium

Advertisement

Sara A. Hurvitz, MD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses phase II results from the TRIO-US B-12 TALENT study, which showed that patients with localized, hormone receptor–positive, HER2-low breast cancer who are treated with fam-trastuzumab deruxtecan-nxki (T-DXd) in the neoadjuvant setting had an overall response rate (ORR) of 68%. When combined with anastrozole, T-DXd led to a 58% ORR. This is the first trial to evaluate T-DXd in HER2-low breast cancer, a potentially curable disease (Abstract GS2-03).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The TRIO-US B-12 TALENT Clinical Trial was a study aimed to investigate the activity of TDXD, either alone or in combination with endocrine therapy in hormone receptor positive HER2 low breast cancer in the neoadjuvant or curative setting. So treating patients prior to surgery. Why is this important? We know that patients with hormone receptor positive breast cancer treated with neoadjuvant therapy have a very low chance of achieving a pathologic complete response, and even a low chance of a good objective response to therapy, even with multi-agent chemotherapy or CDK-46 inhibitors and endocrine therapy we're not getting great outcomes. TDXD has demonstrated significant benefits in the metastatic hormone receptor positive, HER2 low phase from the Destiny Breast 04 clinical trial, but has not yet been tested in the early stage setting in hormone receptor positive HER2 low disease. So we conducted a very early phase, phase two clinical trial where patients were treated with TDXD alone or with TDXD with anastrozole. Patients had to have stage two or three early stage breast cancer that was ER positive and had to have centrally confirmed HER2 low expression. We evaluated patients and then treated them with six cycles of TDXD, either alone or with anastrozole. And then after we enrolled about half the patients and began to see some near pathologic complete responses, we amended the protocol and extended the length of therapy to eight cycles. We presented at San Antonio our interim data, very preliminary evidence of activity and our observations of how this drugs or drugs work together in this setting. We showed that there was an objective response rate of 68% with TDXD alone and 58% of TDXD plus endocrine therapy from baseline to the time of surgery. So this is an objective response rate. It's important to note the denominator includes patients who haven't yet completed therapy or who came off therapy early. This objective response rate is somewhat kind of like what we saw in the Destiny Breast 04 clinical trial. We also saw one patient have a pathologic complete response, and we saw an additional four patients have a near pathologic complete response in RCB one. So the data are very intriguing. We are still waiting for surgical results from 24% of the patients treated with TDXD and 31% of the patients treated in the combination arm. So it's too early to call a PATH CR rate. But the data that we got, it's very intriguing. It's interesting, and it is allowing us to look at the biomarkers, what's happening to HER2? What's happening in the tumor microenvironment as we treat with TDXD, with or without endocrine therapy. Next year, we plan to report the final results, and I think these results may help inform the design of studies of TDXD in the early stage setting for HER2 low disease.

Related Videos

Breast Cancer

Mafalda Oliveira, MD, PhD, on Camizestrant vs Fulvestrant in Advanced Breast Cancer: New Phase II Results

Mafalda Oliveira, MD, PhD, of Spain’s Vall d’Hebron University Hospital and Institute of Oncology, discusses findings from the SERENA-2 trial, which compared the next-generation selective estrogen receptor degrader camizestrant to fulvestrant in patients with hormone receptor–positive, HER2-negative breast cancer. Camizestrant, which can be taken as a daily pill (as opposed to fulvestrant, which must be given via injection), improved progression-free survival by up to 42% (Abstract GS3-02).

 

Breast Cancer

Joannie M. Ivory, MD, MSPH, and Lisa A. Carey, MD, on PAM50 Subtype and 21-Gene Recurrence Scores in Younger and Black Women With Breast Cancer

Lisa A. Carey, MD, and Joannie M. Ivory, MD, MSPH, both of the University of North Carolina at Chapel Hill, discuss the higher frequency and treatment implications of nonluminal A or high-risk tumors in Black and younger women. In this study, PAM50 and 21-gene assays revealed different demographic patterns by race and age (Abstract PD1-08).

Breast Cancer

Erica L. Mayer, MD, PhD, on Metastatic Breast Cancer: New Findings on Palbociclib After Prior CDK4/6 Inhibitor and Endocrine Therapy

Erica L. Mayer, MD, PhD, of Dana-Farber Cancer Institute, discusses findings from the PACE study of patients with endocrine- and CDK4/6 inhibitor–pretreated estrogen receptor–positive/HER2-negative metastatic breast cancer who were randomly assigned to fulvestrant alone; fulvestrant and palbociclib; or fulvestrant, palbociclib, and avelumab. Combining palbociclib with fulvestrant beyond disease progression on a prior CDK4/6 inhibitor regimen did not improve progression-free survival compared with fulvestrant alone. A longer progression-free survival when a PD-L1 inhibitor was added to fulvestrant and palbociclib deserves further study. A baseline circulating tumor DNA analysis suggests that the potential benefit of palbociclib after progression on a prior CDK4/6 inhibitor may be influenced by ESR1 or PIK3CA status (Abstract GS3-06).

Breast Cancer

Per Karlsson, MD, PhD: New Data on Breast-Conserving Surgery, With or Without Radiotherapy

Per Karlsson, MD, PhD, of Sweden’s University of Gothenburg and the Sahlgrenska Comprehensive Cancer Center, discusses results from the POLAR study, which was a meta-analysis of three clinical trials of breast-conserving surgery with or without radiotherapy. POLAR is the first genomic classifier that appears not only to be prognostic for locoregional recurrence, but also predictive of radiotherapy benefit. Although patients with breast cancer who had a high POLAR score benefited from radiotherapy, patients with a low score did not, and may be candidates for omission of radiotherapy after breast-conserving surgery (Abstract GS4-03).

Breast Cancer

Prudence A. Francis, MD, on Premenopausal ER-Positive Breast Cancer: Past, Present, and Future

Prudence A. Francis, MD, of the Peter MacCallum Cancer Centre, discusses an update of the SOFT trial, which showed that adding ovarian function suppression (OFS) to adjuvant tamoxifen for premenopausal women with estrogen receptor (ER)-positive breast cancer reduces the risk of recurrence. OFS enables the use of adjuvant aromatase inhibitors as an alternative to tamoxifen, which can further reduce recurrence of ER-positive, HER2-negative disease. Very young women—those younger than 35 years old—should be considered for OFS, according to Dr. Francis. In addition, tamoxifen alone is appropriate in women with low-risk clinical-pathologic features.

Advertisement

Advertisement




Advertisement